Insulin resistance is associated with increased cholesterol synthesis, decreased cholesterol absorption and enhanced lipid response to statin therapy

Atherosclerosis

Volumn 211, Issue 1, 2010, Pages 260-265

  Hoenig, Michel R ^a   Sellke, Frank W ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b BROWN UNIVERSITY   (United States)

Author keywords

Cholesterol; Cholesterol metabolism; Insulin resistance; Personalized medicine; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTANOL; CHOLESTEROL; CLOPIDOGREL; DESMOSTEROL; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LATHOSTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SITOSTEROL; THIAZIDE DIURETIC AGENT; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ABDOMINAL AORTA ANEURYSM; ABSORPTION; AGED; ARTICLE; BRAIN ISCHEMIA; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MUSCLE DISEASE; PATIENT COMPLIANCE; PERIPHERAL VASCULAR DISEASE; PHARMACOGENOMICS; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; BIOSYNTHESIS; BLOOD; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED;

AGED; CHOLESTEROL; CHOLESTEROL, LDL; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN RESISTANCE; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PYRROLES;

EID: 77954309748     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.02.029     Document Type: Article

References (19)

1. Ballantyne C.M., Olsson A.G., Cook T.J., et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001, 104:3046-3051.
2. Robinson J.G., Smith B., Maheshwari N., Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005, 46:1855-1862.
3. Hoenig M.R., Kostner K.M., Read S.J., Walker P.J., Atherton J.J. Implications of the obesity epidemic for statin therapy: shifting cholesterol metabolism to a high synthesis and low dietary absorption state. Endocr Metab Immune Disord Drug Targets 2007, 7:153-166.
4. Gylling H., Miettinen T.A. Inheritance of cholesterol metabolism of probands with high or low cholesterol absorption. J Lipid Res 2002, 43:1472-1476. (10.1194/jlr.M200155-JLR200).
5. Miettinen T.A., Gylling H., Strandberg T., Sarna S. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. BMJ 1998, 316:1127-1130.
6. Pihlajamaki J., Gylling H., Miettinen T.A., Laakso M. Insulin resistance is associated with increased cholesterol synthesis and decreased cholesterol absorption in normoglycemic men. J Lipid Res 2004, 45:507-512.
7. Simonen P., Gylling H., Howard A.N., Miettinen T.A. Introducing a new component of the metabolic syndrome: low cholesterol absorption. Am J Clin Nutr 2000, 72:82-88.
8. Angelin B., Backman L., Einarsson K., Eriksson L., Ewerth S. Hepatic cholesterol metabolism in obesity: activity of microsomal 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Lipid Res 1982, 23:770-773.
9. Miettinen T.A., Gylling H. Ineffective decrease of serum cholesterol by simvastatin in a subgroup of hypercholesterolemic coronary patients. Atherosclerosis 2002, 164:147-152.
10. Muniyappa R., Lee S., Chen H., Quon M.J. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008, 294:E15-26.
11. Sarafidis P.A, Lasaridis A.N., Nilsson P.M., et al. Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type II diabetes. J Hum Hypertens 2007, 21:709-716.
12. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care 2004, 27:1487-1495.
13. Voora D., Shah S.H., Reed C.R., et al. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circ Cardiovasc Genet 2008, 1:100-106.
14. Thompson J.F., Hyde C.L., Wood L.S., et al. Comprehensive whole genome and candidate gene analysis for response to statin therapy in TNT cohort. Circ Cardiovasc Genet 2009, 2:173-181.
15. Thompson J.F., Man M., Johnson K.J., et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 2005, 5:352-358.
16. Hoenig M.R. Implications of the obesity epidemic for lipid-lowering therapy: non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target. Vasc Health Risk Manag 2008, 4:143-156.
17. Bhatt D.L., Steg P.G., Ohman E.M., et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006, 295:180-189.
18. Grundy S.M, Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
19. O'Keefe J.H., Cordain L., Harris W.H., Moe R.M., Vogel R. Optimal low-density lipoprotein is 50 to 70mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 2004, 43:2142-2146.